JP2024505630A - 医薬製剤 - Google Patents

医薬製剤 Download PDF

Info

Publication number
JP2024505630A
JP2024505630A JP2023542980A JP2023542980A JP2024505630A JP 2024505630 A JP2024505630 A JP 2024505630A JP 2023542980 A JP2023542980 A JP 2023542980A JP 2023542980 A JP2023542980 A JP 2023542980A JP 2024505630 A JP2024505630 A JP 2024505630A
Authority
JP
Japan
Prior art keywords
semi
compound
pharmaceutical formulation
solid
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023542980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505630A5 (https=
Inventor
アーマー，リチャード
マタス，マルセル デ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redx Pharma Ltd
Original Assignee
Redx Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redx Pharma Ltd filed Critical Redx Pharma Ltd
Publication of JP2024505630A publication Critical patent/JP2024505630A/ja
Publication of JP2024505630A5 publication Critical patent/JP2024505630A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023542980A 2021-01-15 2022-01-14 医薬製剤 Pending JP2024505630A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2100526.9A GB202100526D0 (en) 2021-01-15 2021-01-15 Pharmaceutical formulation
GB2100526.9 2021-01-15
PCT/GB2022/050083 WO2022153062A1 (en) 2021-01-15 2022-01-14 Pharmaceutical formulation

Publications (2)

Publication Number Publication Date
JP2024505630A true JP2024505630A (ja) 2024-02-07
JP2024505630A5 JP2024505630A5 (https=) 2024-12-04

Family

ID=74678956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542980A Pending JP2024505630A (ja) 2021-01-15 2022-01-14 医薬製剤

Country Status (10)

Country Link
US (1) US20240082244A1 (https=)
EP (1) EP4277606A1 (https=)
JP (1) JP2024505630A (https=)
KR (1) KR20230133285A (https=)
CN (1) CN116710077A (https=)
AU (1) AU2022208241A1 (https=)
CA (1) CA3202029A1 (https=)
GB (1) GB202100526D0 (https=)
MX (1) MX2023008406A (https=)
WO (1) WO2022153062A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017530183A (ja) * 2014-10-08 2017-10-12 レデックス ファーマ ピーエルシーＲｅｄｘ Ｐｈａｒｍａ Ｐｌｃ Ｗｎｔシグナル伝達経路の阻害剤としてのｎ−ピリジニルアセトアミド誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA845180B (en) * 1983-07-07 1986-02-26 American Home Prod Pharmaceutical composition containing a liquid lubricant
US9783550B2 (en) * 2013-05-14 2017-10-10 The Board Of Regents Of The University Of Texas System Highly potent inhibitors of porcupine
CN111971063A (zh) * 2018-04-06 2020-11-20 4阵营疗法公司 通过靶向调节基因信号传导网络治疗疾病

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017530183A (ja) * 2014-10-08 2017-10-12 レデックス ファーマ ピーエルシーＲｅｄｘ Ｐｈａｒｍａ Ｐｌｃ Ｗｎｔシグナル伝達経路の阻害剤としてのｎ−ピリジニルアセトアミド誘導体

Also Published As

Publication number Publication date
AU2022208241A9 (en) 2025-01-09
GB202100526D0 (en) 2021-03-03
MX2023008406A (es) 2023-08-03
EP4277606A1 (en) 2023-11-22
AU2022208241A1 (en) 2023-07-06
US20240082244A1 (en) 2024-03-14
CN116710077A (zh) 2023-09-05
CA3202029A1 (en) 2022-07-21
WO2022153062A1 (en) 2022-07-21
KR20230133285A (ko) 2023-09-19

Similar Documents

Publication Publication Date Title
RU2517135C2 (ru) Композиции пептидов и способы их получения
JP2024037884A (ja) キナーゼ阻害剤の塩およびその組成物
AU762926B2 (en) Methods and compositions for delivery of taxanes
US20030220391A1 (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
TWI233355B (en) Oral formulations for anti-tumor compounds
TW200302734A (en) Pharmaceutical compositions for hepatitis c viral protease inhibitors
JP2024505630A (ja) 医薬製剤
KR20070119700A (ko) 페노피브레이트 및 계면 활성제 혼합물을 함유하는 제제
US10857127B2 (en) Vaginal delivery systems containing selective estrogen receptor modulator (SERM) and uses thereof
TW201919626A (zh) 醫藥組合物
WO2004073692A1 (ja) 難水溶性薬物のハードカプセル剤
JP2023552495A (ja) カンナビノイド作動薬を含む医薬組成物
JP2023508245A (ja) ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１ｈ－ピラゾール－４－イル）－３ｈ－イミダゾ［４，５－ｂ］ピリジンを含む医薬製剤
KR20200015457A (ko) 암포테리신 b의 고형 경구 제형
JP2012001487A (ja) タクロリムス含有カプセル剤
Tiemessen et al. Characteristics of a novel phospholipid-based depot injectable technology for poorly water-soluble drugs
WO2020028508A1 (en) Solid oral formulations of amphotericin b
KR20240053626A (ko) 강화된 sn-38 용해성 및 경구 흡수성을 갖는 제형

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260216